1. Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. (10th December 2017) Authors: Wongchenko, Matthew J.; Ribas, Antoni; Dréno, Brigitte; Ascierto, Paolo A.; McArthur, Grant A.; Gallo, Jorge D.; Rooney, Isabelle A.; Hsu, Jessie; Koeppen, Hartmut; Yan, Yibing; Larkin, James Journal: Pigment cell & melanoma research Issue: Volume 31:Number 4(2018) Page Start: 516 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10240 (13th June 2020) Authors: Gutzmer, Ralf; Stroyakovskiy, Daniil; Gogas, Helen; Robert, Caroline; Lewis, Karl; Protsenko, Svetlana; Pereira, Rodrigo P; Eigentler, Thomas; Rutkowski, Piotr; Demidov, Lev; Manikhas, Georgy Moiseevich; Yan, Yibing; Huang, Kuan-Chieh; Uyei, Anne; McNally, Virginia; McArthur, Grant A; Ascierto, P... Journal: Lancet Issue: Volume 395:Issue 10240(2020) Page Start: 1835 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Graph-theory based degree centrality combined with machine learning algorithms can predict response to treatment with antiepileptic medications in children with epilepsy. (September 2021) Authors: Wang, Xueyu; Hu, Tian; Yang, Qi; Jiao, Dongmei; Yan, Yibing; Liu, Libo Journal: Journal of clinical neuroscience Issue: Volume 91(2021) Page Start: 276 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study. (10th December 2020) Authors: Lewis, Karl; Ascierto, Paolo; Robert, Caroline; Munhoz, Rodrigo; Liszkay, Gabriella; Marino, Luis De La Cruz; Olah, Judit; Queirolo, Paola; Mackiewicz, Jacek; Shah, Kalpit; Forbes, Harper; Hertig, Christian; Yan, Yibing; Gutzmer, Ralf; McArthur, Grant Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A188 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study. (9th November 2020) Authors: Lewis, Karl; Ascierto, Paolo; Robert, Caroline; Munhoz, Rodrigo; Liszkay, Gabriella; Marino, Luis De La Cruz; Olah, Judit; Queirolo, Paola; Mackiewicz, Jacek; Shah, Kalpit; Forbes, Harper; Hertig, Christian; Yan, Yibing; Gutzmer, Ralf; McArthur, Grant Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A334 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Abnormal Functional Connectivity of Thalamic Subdivisions in Alzheimer's Disease: A Functional Magnetic Resonance Imaging Study. (1st August 2022) Authors: Wu, Yue; Wu, Xingqi; Gao, Liying; Yan, Yibing; Geng, Zhi; Zhou, Shanshan; Zhu, Wanqiu; Tian, Yanghua; Yu, Yongqiang; Wei, Ling; Wang, Kai Journal: Neuroscience Issue: Volume 496(2022) Page Start: 73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). Issue 4 (1st February 2021) Authors: Kopetz, Scott; Guthrie, Katherine A.; Morris, Van K.; Lenz, Heinz-Josef; Magliocco, Anthony M.; Maru, Dipen; Yan, Yibing; Lanman, Richard; Manyam, Ganiraju; Hong, David S.; Sorokin, Alexey; Atreya, Chloe E.; Diaz, Luis A.; Allegra, Carmen; Raghav, Kanwal P.; Wang, Stephen E.; Lieu, Christopher H.... Journal: Journal of clinical oncology Issue: Volume 39:Issue 4(2021) Page Start: 285 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. Issue 1 (January 2023) Authors: Ascierto, Paolo A; Stroyakovskiy, Daniil; Gogas, Helen; Robert, Caroline; Lewis, Karl; Protsenko, Svetlana; Pereira, Rodrigo P; Eigentler, Thomas; Rutkowski, Piotr; Demidov, Lev; Zhukova, Natalia; Schachter, Jacob; Yan, Yibing; Caro, Ivor; Hertig, Christian; Xue, Cloris; Kusters, Lieke; McArthur,... Journal: Lancet oncology Issue: Volume 24:Issue 1(2023) Page Start: 33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti–programmed death-1 therapy. (January 2023) Authors: Sandhu, Shahneen; Atkinson, Victoria; Cao, Maria González; Medina, Theresa; Rivas, Ainara Soria; Menzies, Alexander M.; Caro, Ivor; Roberts, Louise; Song, Yuyao; Yan, Yibing; Guo, Yu; Xue, Cloris; Long, Georgina V. Journal: European journal of cancer Issue: Volume 178(2023) Page Start: 180 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Issue 6 (June 2019) Authors: Eng, Cathy; Kim, Tae Won; Bendell, Johanna; Argilés, Guillem; Tebbutt, Niall C; Di Bartolomeo, Maria; Falcone, Alfredo; Fakih, Marwan; Kozloff, Mark; Segal, Neil H; Sobrero, Alberto; Yan, Yibing; Chang, Ilsung; Uyei, Anne; Roberts, Louise; Ciardiello, Fortunato Journal: Lancet oncology Issue: Volume 20:Issue 6(2019) Page Start: 849 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗